Seres Therapeutics (NASDAQ:MCRB) had its price target lowered by stock analysts at Piper Sandler from $40.00 to $32.00 in a research report issued to clients and investors on Thursday, The Fly reports. The brokerage presently has an “overweight” rating on the biotechnology company’s stock. Piper Sandler’s price target suggests a potential upside of 303.02% from the stock’s current price.
Several other equities research analysts have also recently issued reports on MCRB. Chardan Capital started coverage on shares of Seres Therapeutics in a research report on Friday, July 9th. They set a “buy” rating and a $30.00 price objective for the company. HC Wainwright increased their target price on shares of Seres Therapeutics from $41.00 to $46.00 and gave the stock a “buy” rating in a research note on Wednesday, May 5th. Finally, Zacks Investment Research raised shares of Seres Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, July 8th. Two analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of $36.17.
Shares of NASDAQ MCRB traded down $12.89 during mid-day trading on Thursday, reaching $7.94. The company’s stock had a trading volume of 643,351 shares, compared to its average volume of 986,181. The business has a 50-day simple moving average of $21.21. The firm has a market cap of $727.94 million, a PE ratio of -6.56 and a beta of 3.93. The company has a quick ratio of 5.26, a current ratio of 5.26 and a debt-to-equity ratio of 0.15. Seres Therapeutics has a 1-year low of $3.67 and a 1-year high of $38.50.
Institutional investors have recently modified their holdings of the stock. Orion Capital Management LLC purchased a new position in Seres Therapeutics in the fourth quarter worth approximately $25,000. Meeder Asset Management Inc. purchased a new position in Seres Therapeutics in the first quarter worth approximately $26,000. Quantbot Technologies LP lifted its stake in Seres Therapeutics by 162.5% in the first quarter. Quantbot Technologies LP now owns 2,100 shares of the biotechnology company’s stock worth $43,000 after acquiring an additional 1,300 shares during the last quarter. Penserra Capital Management LLC raised its holdings in Seres Therapeutics by 174.2% during the fourth quarter. Penserra Capital Management LLC now owns 2,095 shares of the biotechnology company’s stock worth $51,000 after purchasing an additional 1,331 shares in the last quarter. Finally, Point72 Hong Kong Ltd raised its holdings in Seres Therapeutics by 14.4% during the first quarter. Point72 Hong Kong Ltd now owns 4,354 shares of the biotechnology company’s stock worth $90,000 after purchasing an additional 547 shares in the last quarter. Institutional investors own 98.12% of the company’s stock.
Seres Therapeutics Company Profile
Seres Therapeutics, Inc, a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the treatment of clostridium difficile infection (CDI).
Recommended Story: How to calculate the annual rate of depreciation
Receive News & Ratings for Seres Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.